www.standoutstocks.com: stocks That Standout For August 11th, 2009 are NVSR, EGMI, ICNB, NNVC, GETA

Aug 11, 2009 (M2 PRESSWIRE via COMTEX) -- NVSR | Quote | Chart | News | PowerRating -- www.StandoutStocks.com: Stocks That Standout For Aug. 11th, 2009 are NavStar Technologies, Inc. (PINKSHEETS: NVSR),Electronic Game Card, Inc. (OTCBB: EGMI), Iconic Brands, Inc. ("Iconic") (OTCBB: ICNB), NanoViricides, Inc. (OTCBB: NNVC.OB), Genta Incorporated (OTCBB: GETA)

Visit Us On Twitter and Facebook: http://twitter.com/StandoutStocks http://www.facebook.com/people/Standout-Stocks/547603354 Sign-up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER at HYPERLINK "http://www.Standoutstocks.com/" www.Standoutstocks.com

NavStar Technologies, Inc. Begins Procedures to Uplist on Pinksheets, From Limited to Current Information

ANAHEIM, CA, Aug 11, 2009-- NavStar Technologies, Inc. (PINKSHEETS: NVSR), a multinational firm focused on developing and commercializing asset tracking and monitoring devices for vehicles and high value cargo, today announced that it is undertaking all measures necessary in order to become listed as a Current Information Company on Pinksheets.com listings.

"We are pleased to announce that we will be submitting all necessary filings in order to be listed as a Current Information Company with Pinksheets.com. This is one of many steps we are planning in order to become a fully listed OTCBB company. Such a move can only prove beneficial to our shareholders in permitting us to be completely transparent and as such gain the confidence of our investors," said N. Douglas Pritt, Chairman & CEO, NavStar Technologies, Inc. "This decision is consistent with our long term plans for expansion, growth and development. Our company has come a long way and we feel that the best is yet to come." FORWARD-LOOKING STATEMENT This press release contains forward-looking statements within the meaning of US federal securities laws, that involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied in this press release.

About NavStar Technologies, Inc.

NavStar (www.navstarinc.com) is focused on the creation of products and services that provide tracking and monitoring of vehicles and high value cargo, equipment, and other valuable and personal assets.

Electronic Game Card, Inc. Appoints New U.S. Based Chief Financial Officer NEW YORK and LONDON, Aug 10, 2009 -- Electronic Game Card, Inc. (OTC Bulletin Board: EGMI | Quote | Chart | News | PowerRating) ("EGC"), announced today that it has appointed Thomas E. Schiff as its chief financial officer effective September 1, 2009, replacing Linden J. Boyne who is retiring after serving as ECG's interim chief financial officer, corporate secretary and board member over the last three years. Mr. Schiff, formerly a certified public accountant with over 15 years of public and private company CFO experience, will work from the Company's new headquarters to be located in Irvine, CA.

Mr. Schiff brings over 30 years of executive experience in the gaming, electronic security, marketing and manufacturing industries. He received his CPA certification while at KPMG (formerly Peat, Marwick & Mitchell) where he was an audit services and computer audit specialist. He also holds an MBA and a Bachelor of Arts degree in economics from Stanford University. Mr. Schiff previously served as executive vice president and CFO for Planetwide Games, Inc., interactive entertainment software and digital media company, where he was actively involved in the transition of the company from development stage into commercialization, executed license agreements with entities such as Electronic Arts, Sony Online Entertainment, National Geographic, Marvel Characters, and Viacom/Paramount Pictures. Prior to this he was executive vice president and CFO of SSP Solutions, Inc., a digital security company providing PKI-based solutions, where he managed two mergers, multiple complex financings and significantly reduced expenses. From 1996 to 2000, Mr. Schiff was chief financial officer for Gotcha International, L.P., an international trademark licensor of apparel products, responsible for the structuring and negotiations of numerous business ventures.

Commenting on Mr. Schiff's appointment, Kevin Donovan, EGC's chief executive officer, said, "Our search for a highly qualified financial executive with relevant industry and public company experience was extensive. Tom Schiff has stellar credentials and an entrepreneurial enthusiasm that should prove instrumental in accomplishing our mission of achieving EGC's market potential. Throughout his career, Tom has worked through restructurings, turnarounds and importantly business expansions, establishing proper financial controls and improving processes and performance. We expect Tom to be a vital part of our management team as we build our client base, develop strategic partnerships, and expand our platform." "This is an exciting time in Electronic Game Card's evolution. The company has completed its turnaround, entered its commercialization phase while establishing a healthy financial base," commented Tom Schiff. "Having successfully guided a number of companies through significant transitional and high growth periods, I am eager to become part of EGC's management team to participate in its further development. The company is poised for significant business expansion as it secures enterprise contracts and joint venture partnerships." The Board of Directors of Electronic Game Card, Inc. wishes to thank Linden Boyne for his efforts during the last three years. He was instrumental, along with Lee Cole the former interim CEO of EGC, in giving the Company the foundation it now has, and we wish him good health and happiness in the future.

About Electronic Game Card, Inc.

Electronic Game Card, Inc., (OTC Bulletin Board: EGMI), develops, produces and markets innovative games to the promotional industry worldwide, toys and games, casinos and lottery. The Company's lead product is the EGC Electronic GameCard(TM), a unique credit card-sized pocket game combining patent and patent-pending proprietary technology of interactive capability with "instant win" excitement. The EGC Electronic GameCard(TM) can be programmed to suit a variety of gaming and promotion applications.

EGMI's client base extends across the $100 billion global market of sales promotion, gaming and casinos, Indian gaming and state and national lotteries markets. EGMI develops sales and marketing relationships with agents and distributors globally and currently has agents and distributors in North America, United Kingdom, Ireland, Mexico, Italy, Sweden, Norway, Denmark, Finland, South Africa Australia, New Zealand and Japan.

For further information please visit www.electronicgamecard.com.

Certain statements in this news release may constitute "forward-looking" statements within the meaning of section 21E of the Securities and Exchange Act of 1934. The Company believes that its expectations, as expressed in these statements are based on reasonable assumptions regarding the risks and uncertainties inherent in achieving those expectations. These statements are not, however, guarantees of future performance and actual results may differ materially. Risk factors are listed in the most recent Annual Report on Form 10-KSB and Quarterly Report on Form 10-QSB filed with the Securities and Exchange Commission

Iconic Brands/ICNB Signs Second National Restaurant Chain, Sullivan's Steakhouse LINDENHURST, N.Y., Aug 10, 2009 -- Iconic Brands, Inc. ("Iconic") (OTCBB: ICNB | Quote | Chart | News | PowerRating) a developer and marketer of the highest quality, celebrity branded alcoholic beverages, today announced that Iconic has signed a second national restaurant chain, Del Frisco's Restaurant Group to carry Danny DeVito's Premium Limoncello. DFRG includes 19 Sullivan's Steakhouses and 8 Del Frisco's Double Eagle Steakhouses throughout the US. Iconic plans to kick-off the brand at the Del Frisco's in Las Vegas on August 24th as well as doing a launch party with a personal appearance by Mr. DeVito at a Sullivan's location, to be announced at a later date. Tammy LaNasa, Corporate Beverage Director, said "Danny's Limoncello is a great product and we are looking forward to representing the brand." Earlier this year, Iconic signed Planet Hollywood's Buca di Beppo ("Buca") to also carry Danny DeVito's Premium Limoncello; launching the product at Buca's District of Columbus location with Mr. DeVito himself and his friends, Sylvester Stallone and Charlie Sheen. The photogs, videographers and reporters from many different publications attended the successful launch seen in this link: Buca's Limoncello Launch Buca di Beppo, owned and operated by Planet Hollywood, has 100 highly acclaimed immigrant Southern Italian restaurants nationwide. Dishes enjoyed for generations in villages throughout Italy inspire their menu, giving Buca its authentic Italian flare. Made from organic lemons grown on the Sorrento Peninsula in Southern Italy, Danny DeVito's Premium Limoncello fits wonderfully in Buca's spirit and wine selection.

"This is an exciting time for our Company as we continue to aggressively market Danny DeVito's Premium Limoncello into national restaurant chains," said Richard DeCicco, CEO of Iconic. "Both Buca and Sullivan's are great introductions into the restaurant market and we look forward to establishing a strong following of patrons in these restaurants. As our brand and Company gains momentum in the marketplace, we expect to sign additional nationwide chains to carry Danny's Limoncello as well as our other celebrity branded spirits." To sign up for upcoming events sponsored by Iconic, please go to www.corporateevolutions.com About Iconic Brands, Inc.

Headquartered in Lindenhurst, New York, Iconic Brands Inc. develops, markets and distributes the highest quality, celebrity branded alcoholic beverages by capitalizing on the ability to procure superior and unique products from around the world and brand the products with internationally recognized celebrities. The Company is led by CEO Richard DeCicco, a beverage industry innovator with over three decades of experience in the global beverage alcohol business. Iconic Brands Inc. is a federally licensed importer and distributor of alcoholic beverages as well as a licensed New York State wholesaler, maintaining a federal customs bonded warehouse.

More information about the Company may be found at www.iconicbrandsusa.com Forward-Looking Statements Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of Iconic Brands, Inc. can be found in the filings of Iconic Brands, Inc. with the U.S. Securities and Exchange Commission.

NanoViricides, Inc. Anti-Herpes Drug Candidate Reduces Viral Load by 99.99%

WEST HAVEN, Conn., Aug 10, 2009-- NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that the herpes simplex viral load was reduced by 99.99% or 10,000 fold in in-vitro studies by nanoviricides(TM) drug candidates. The studies were performed by Thevac in Baton Rouge, LA, in collaboration with the Division of Biotechnology and Molecular Medicine at the LSU School of Veterinary Medicine under the supervision of Dr. Gus Kousoulas.

Four different nanoviricides showed greater than 10,000-fold (>99.99%) reduction in virus quantity compared to untreated controls in a cell culture assay employing the LSU proprietary green-fluorescent-protein-tagged (GFP) modified HSV-1 McKrae strain.

These nanoviricide drug candidates are designed to act against all herpes simplex virus strains, including HSV-1 and HSV-2. The Company has commissioned additional in vitro studies to confirm the results. Animal studies have also been scheduled.

"We are very excited with this success against HSV-1," said Eugene Seymour, MD, MPH, CEO of the Company, adding "and expect this to lead to a topical skin cream against herpes cold sores and genital herpes. This opens up another significant commercial opportunity for the Company." Herpes simplex virus (HSV) causes "cold sores", the incidence of which is second only to the common cold (100 million recurrences annually in the US alone). In addition, genital herpes prevalence is 67 million infected individuals in the US alone. HSV also causes keratitis, a disease of the eye (250,000 US cases/year).

Existing therapies include acyclovir and drugs chemically related to it. These drugs, nucleoside analogs, act by inhibiting viral DNA synthesis. However, there is known drug toxicity due to interference with human metabolism. Currently, there is no cure for herpes infection.

Nanoviricides act by a novel and distinctly different mechanism compared to existing drugs. Nanoviricides are designed to mimic the human cell surface to which the virus binds. Our results suggest that a nanoviricide could become a highly sought after drug against HSV.

The market size for herpes simplex virus treatments is in excess of $2 billion annually.

About NanoViricides: NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide(TM) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital herpes, viral diseases of the eye including EKC, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

SOURCE: NanoViricides, Inc.

Genta Incorporated to Host Conference Call to Discuss Second Quarter 2009 Highlights and Financial Results

BERKELEY HEIGHTS, N.J., Aug 10, 2009 -- Genta Incorporated (OTCBB: GETA | Quote | Chart | News | PowerRating) announced that the Company will release its second quarter 2009 financial results on Friday, August 14, 2009. Genta management will host a conference call and live audio webcast to discuss financial results and recent corporate activities at 8:00 am EDT.

Participants can access the live call by dialing (877) 634-8606 (U.S. and Canada) or (973) 200-3973 (International). The access code for the live call is Genta Incorporated. The call will also be webcast live at http:www.genta.com/investorrelation/events.html For investors unable to participate in the live call, a replay will be available approximately two hours after the completion of the call, and will be archived for 30 days. Access numbers for this replay are: (800) 642-1687 (U.S. and Canada) and (706) 645-9291 (International); conference ID number is: 22633873.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, which has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: www.genta.com.

Safe Harbor This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Such forward-looking statements include those that express plan, anticipation, intent, contingency, goals, targets, or future developments and/or otherwise are not statements of historical fact. The words "potentially", "anticipate", "could", "calls for", and similar expressions also identify forward-looking statements. The Company does not undertake to update any forward-looking statements. Factors that could affect actual results include, without limitation, risks associated with: -- the Company's ability to obtain necessary regulatory approval for Genasense(R) from the U.S. Food and Drug Administration ("FDA"); -- the safety and efficacy of the Company's products or product candidates; -- the Company's assessment of its clinical trials; -- the commencement and completion of clinical trials; -- the Company's ability to develop, manufacture, license and sell its products or product candidates; -- the Company's ability to enter into and successfully execute license and collaborative agreements, if any; -- the adequacy of the Company's capital resources and cash flow projections, the Company's ability to obtain sufficient financing to maintain the Company's planned operations, or the Company's risk of bankruptcy; -- the adequacy of the Company's patents and proprietary rights; -- the impact of litigation that has been brought against the Company; and -- the other risks described under Certain Risks and Uncertainties Related to the Company's Business, as contained in the Company's Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2008 and its most recent quarterly report on Form 10-Q.

About Standoutstocks.com

www.Standoutstocks.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies.

www.Standoutstocks.com email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Standout StocksReport home page at http://www.Standoutstocks.com and select the "join now" button.

Join us at http://www.standoutstocks.com for a complimentary subscription to the most exciting online financial newsletter on the market.

Disclaimer: Verify all claims and do your own due diligence. Standoutstocks.com profiles are not a solicitation or recommendation to buy, sell or hold securities. Standoutstocks.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Standoutstocks.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), Standoutstocks.com is owned and operated by Standoutstocks.com. Neither Standoutstocks.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Standoutstocks.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Standoutstocks.com statements and opinions and such statements and opinions cannot be considered independent. Standoutstocks.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Standoutstocks.com services are often paid for using free-trading shares. Standoutstocks.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Visit us for a full Disclaimer at: http://www.standoutstocks.com/disclaimer.aspx CONTACT: Jason A. Hilton, Standout Stocks Tel: +1 585 729 8809 e-mail: Jason@Newmediaadvisorsllc.com e-mail: mailto:info@standoutstocks.com CONTACT: Jason A. Hilton, Standout Stocks Tel: +1 585 729 8809 e-mail: Jason@Newmediaadvisorsllc.com e-mail: mailto:info@standoutstocks.com WWW: http://www.standoutstocks.com

CONTACT: Jason A Hilton, Standout Stocks Tel: +1 585 729 8809 e-mail: Jason@Newmediaadvisorsllc.com e-mail: info@standoutstocks.com WWW: http://www.standoutstocks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index